SEARL signs license agreement with Mabwell for biological medicines

MG News | July 12, 2023 at 03:09 PM GMT+05:00

Add Mettisglobal as a Trusted Source on Google

0:00

July 12, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has entered into a License Agreement with Mabwell Pharmaceuticals, China, the latest company’s filing showed.

Under this agreement, the company will manufacture, register, and market the Denosumab Biosimilars drugs in Pakistan.

This partnership will benefit the patients in Pakistan by providing high quality affordable biological medicines.

“The company is committed to increasing its portfolio of products and business which will enhance the quality of its earnings and shareholders' value,” It reads.

Mabwell Pharmaceuticals is an innovative biopharmaceutical company.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	174,429.93 266.16M	-0.97% -1703.64
ALLSHR	105,686.64 690.97M	-0.83% -882.18
KSE30	52,098.85 92.59M	-1.07% -565.05
KMI30	245,280.51 99.76M	-1.03% -2557.91
KMIALLSHR	67,681.60 339.32M	-0.84% -574.20
BKTi	49,745.96 31.42M	-0.99% -497.94
OGTi	34,431.76 6.26M	-0.55% -190.66

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	65,990.00	66,165.00 65,970.00	-20.00 -0.03%
BRENT CRUDE	95.50	95.63 91.31	4.49 4.93%
RICHARDS BAY COAL MONTHLY	105.75	0.00 0.00	-1.25 -1.17%
ROTTERDAM COAL MONTHLY	119.65	0.00 0.00	-0.45 -0.37%
USD RBD PALM OLEIN	1,135.00	1,135.00 1,135.00	0.00 0.00%
CRUDE OIL - WTI	87.90	88.40 87.32	1.07 1.23%
SUGAR #11 WORLD	14.75	14.94 14.67	-0.13 -0.87%